Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Patrick J. Haley sold 41,588 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the completion of the sale, the executive vice president now owns 288,665 shares in the company, valued at $9,918,529.40. This represents a 12.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Exelixis Stock Down 0.3 %
Shares of EXEL stock opened at $34.41 on Wednesday. The stock has a 50-day simple moving average of $29.39 and a 200 day simple moving average of $25.35. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.60. The stock has a market capitalization of $9.83 billion, a P/E ratio of 22.06, a P/E/G ratio of 0.88 and a beta of 0.51.
Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same quarter in the previous year, the company posted $0.10 EPS. The business's revenue was up 14.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.68 earnings per share for the current year.
Analysts Set New Price Targets
50-year Wall Street legend: “Sell this tech stock NOW”
From Chaikin Analytics | Ad
Something very strange is happening to U.S. stocks following President Trump's victory...
And this could spell disaster for some of America's favorite tech companies.
You can watch for it for free, right here.
A number of equities research analysts have commented on the company. Stephens increased their target price on Exelixis from $23.00 to $29.00 and gave the company an "equal weight" rating in a report on Wednesday, October 30th. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 price objective on shares of Exelixis in a research note on Friday, October 11th. Guggenheim boosted their target price on shares of Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Piper Sandler raised their price target on shares of Exelixis from $33.00 to $36.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Finally, BMO Capital Markets boosted their price objective on shares of Exelixis from $29.00 to $36.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Exelixis presently has an average rating of "Moderate Buy" and a consensus price target of $31.44.
Get Our Latest Analysis on Exelixis
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of EXEL. Farallon Capital Management LLC grew its holdings in shares of Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company's stock worth $608,993,000 after acquiring an additional 424,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in Exelixis by 0.4% in the 2nd quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company's stock worth $340,714,000 after purchasing an additional 61,350 shares in the last quarter. LSV Asset Management raised its holdings in Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company's stock worth $129,511,000 after buying an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP lifted its stake in Exelixis by 7.3% during the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company's stock valued at $115,434,000 after buying an additional 349,837 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Exelixis by 12.7% in the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company's stock worth $73,425,000 after buying an additional 370,199 shares during the period. Institutional investors own 85.27% of the company's stock.
About Exelixis
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
